Evidence map›Paper›PMID 34494020›Full record

ArticlebioRxiv : the preprint server for biology2021

Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikes.

Yang Liu, Jianying Liu, Jing Zou, Ping Ren, Scott C Weaver, Xuping Xie, Pei-Yong Shi

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 8 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yang LiuDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, U.S.A.
Jianying LiuDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, U.S.A.
Jing ZouDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, U.S.A.
Ping RenDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, U.S.A.
Scott C WeaverDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston TX, U.S.A.
Xuping XieDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, U.S.A.
Pei-Yong ShiDepartment of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston TX, U.S.A.
The University of Texas Medical Branch at Galveston · US

Funding

UTMB Clinical and Translational Science AwardUL1TR001439 · NCATS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI URBAN, RANDALL J · 2015 to 2024
$40.0M
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
Regulation of Ebola virus replication by the host ubiquitin systemR01AI134907 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GIRALDO, MARIA ISABEL · 2018 to 2022
$3.1M
Discovery and Development of Broad-spectrum Protease Inhibitors of Flaviviruses of Significant Public Health ThreatsR43AI145617 · NIAID · PLEX PHARMACEUTICALS, INC. · PI REMACLE, ALBERT, THOTA, SAMBAIAH · 2020 to 2021
$600k
NCATS NIH HHS UL1 TR001439NIAID NIH HHS HHSN272201600013CNIAID NIH HHS R01 AI134907NIAID NIH HHS R24 AI120942NIAID NIH HHS R43 AI145617
6 · The paper itself

Abstract

The rapid evolution of SARS-CoV-2 mandates a better understanding of cross-protection between variants after vaccination or infection, but studies directly evaluating such cross-protection are lacking. Here we report that immunization with different variant spikes elicits distinct neutralizing kinetics and magnitudes against other SARS-CoV-2 variants. After immunizing hamsters with wild-type or mutant SARS-CoV-2 bearing variant spikes from Alpha, Beta, Gamma, or Epsilon, the animals developed faster and greater neutralization activities against homologous SARS-CoV-2 variants than heterologous variants, including Delta. The rank of neutralizing titers against different heterologous variants varied, depending on the immunized variant spikes. The differences in neutralizing titers between homologous and heterologous variants were as large as 62-, 15-, and 9.7-fold at days 14, 28, and 45 post-immunization, respectively. Nevertheless, all immunized hamsters were protected from challenges with all SARS-CoV-2 variants, including those exhibiting the lowest neutralizing antibody titers. The results provide insights into the COVID-19 vaccine booster strategies.

Identifiers

PMID34494020
PMCPMC8423216
OpenAlexW3196733392

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.